Close Sidebar
Nordic Life Science
Now Reading
Acturum takes over AstraZeneca facilities
Search for content, post, videos
Search for content, post, videos
Advertisement

Acturum takes over AstraZeneca facilities

February 27, 2013
4721 Views

AstraZeneca’s facility Snäckviken in Södertälje has been acquired by Acturum and will from now on be called BiovationPark Telge. The facility will host SP process development, Scania, Campus Telge and around 20 small research companies.
Besides laboratories and offices, Acturum will install 5000 laboratory instruments at the facility. Astra will also hand over 15 drug development projects in neuroscience and pain research as part of the deal. Acturum is owned by PEAB and FAM-Foundation Asset Management. The facilities cover 130 000 square meters.

Related Posts

August 6, 2013

The European Medicines Agency, EMA, has concluded that GLP-1 based treatments do not pose new safety concerns for patients with type 2 diabetes. Earlier this year, a study was published that indicated that drugs based on GLP-1 increase the risk of developing pancreatitis and pre-cancerous cellular changes called pancreatic duct…

January 9, 2014

The U.S. Food and Drug Administration and the European Medicines Agency (EMA) have announced the launch of a joint initiative to share information on inspections of bioequivalence studies submitted in support of generic drug approvals. This collaborative effort provides a mechanism to conduct joint facility inspections for generic drug applications…

AstraZeneca
February 3, 2016

The European Commission has granted conditional marketing authorisation for AstraZeneca’s TAGRISSO, 80mg once-daily tablets for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC). Osimertinib is indicated for patients with T790M mutation-positive NSCLC, irrespective of previous treatment…

January 30, 2014

The drug maker is to close its Avishkar R&D centre  in Bangalore, India, and move parts of its research to Great Britain. The move that will impact 168 employees and early-stage research on tuberculosis and malaria. The decision to shut the R&D centre is said to be part of an ongoing global…